Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Laura Path Recall > Immunomodulatory Therapies > Flashcards

Immunomodulatory Therapies Flashcards

1
Q

MOA: Corticosteroids

A

Inhibit phospholipase A2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Inhibit phospholipase A2

A

MOA: Corticosteroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

MOA: Tacrolimus

A

Calcinurin Inhibitor, block cytokine transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MOA: Cyclosporin

A

Calcinurin Inhibitor, block cytokine transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Calcinurin Inhibitor, block cytokine transcription (x2)

A

Tacrolimus, cyclosporin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MOA: Tofacitinib

A

JAK inhibitor, inhibits cell signalling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

JAK inhibitor, inhibits cell signalling

A

Tofacitinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MOA: Sirolimus

A

blocks clonal T cell proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

MOA: Apremilast

A

PDE4 inhibitor, inhibits cell signalling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PDE4 inhibitor, inhibits cell signalling

A

Apremilast

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA: Basiliximab

A

ab vs. CD25, anti-IL2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ab against CD25 on IL-2 receptor (x2)

A

Basiliximab, Daclizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Indication: Basiliximab, Daclizumab

A

Rejection prophylaxis in transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Indication: Tacrolimus

A

Rejection prophylaxis in transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Indication: Cyclosporin

A

Rejection prophylaxis in transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Indication: Sirolimus

A

Rejection prophylaxis in transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Indication: Tofacitinib

A

Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Indication: Apremilast

A

Psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Indication: Abatacept

A

Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MOA: Abatacept

A

CTLA4-Ig fusion protein, (directed against cell surface antigens to ↓T cell activation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CTLA4-Ig fusion protein, (directed against cell surface antigens to ↓T cell activation)

A

Abatacept

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

MOA: Rituximab

A

ab vs. CD20, depletes mature B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

ab vs. CD20, depletes mature B cells

A

Rituximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Indications: Rituximab

A

RhA, SLE, lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

MOA: Toclizumab

A

ab vs. IL-6 receptor, ↓activation of neuts, B/T cells, macrophages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

ab vs. IL-6 receptor, ↓activation of neuts, B/T cells, macrophages

A

Toclizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Indications: Toclizumab

A

Castleman’s disease, Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

MOA: Natalizumab

A

ab vs. a4 integrin, ↓T cell migration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

ab vs. a4 integrin, ↓T cell migration

A

Natalizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Indications: Natalizumab

A

active MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

MOA: Daclizumab

A

ab against CD25 on IL-2 receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

MOA: Alemtuzumab

A

ab vs. CD52, ↓lymphocytes

33
Q

ab vs. CD52, ↓lymphocytes

A

Alemtuzumab

34
Q

Indications: Alemtuzumab

A

MS, CLL

35
Q

MOA: Muromonab-CD3

A

Blocks CD3 on T cell

36
Q

Blocks CD3 on T cell

A

Muromonab-CD3

37
Q

Indications: Muromonab-CD3

A

Active transplant rejection

38
Q

MOA: Efalizumab

A

anti CD-IIa, ↓T cell migration

39
Q

anti CD-IIa, ↓T cell migration

A

Efalizumab

40
Q

Indications: Efalizumab

A

AI disease

41
Q

MOA: Anti-thymocyte globulin

A

(rabbit), modulates T cell activation and migration, ↓lymphocytes

42
Q

(rabbit), modulates T cell activation and migration, ↓lymphocytes

A

Anti-thymocyte globulin

43
Q

Indications: Anti-thymocyte globulin

A

Acute transplant rejection

44
Q

MOA: Methotrexate

A

Inhibits DHFR, anti-proliferative agent

45
Q

Inhibits DHFR, anti-proliferative agent

A

Methotrexate

46
Q

Indications: Methotrexate

A

RhA, psoriasis, Crohn’s, chemo, abortifacient

47
Q

MOA: Cyclophosphamide

A

alkylates guanine bases of DNA
B>T cells
Anti-proliferative agent

48
Q

alkylates guanine bases of DNA
B>T cells
Anti-proliferative agent

A

Cyclophosphamide

49
Q

Indications: Cyclophosphamide

A

Connetive tissue disease, vasculitis with end organ damage

50
Q

MOA: Azathioprine

A

Blocks purine synthesis
T cells
Anti-metabolic, (converted to 6-mercaptopurine)
Anti-proliferative agent

51
Q

Blocks purine synthesis
T cells
Anti-metabolic, (converted to 6-mercaptopurine)
Anti-proliferative agent

A

Azathioprine

52
Q

Indications: Azathioprine

A

Transplant, AI disease, auto-inflammatory diseases (eg. Crohn’s disease, UC)

53
Q

MOA: Mycophenolate Mofetil

A

Inhibits IM PDH, blocks nucleotide synthesis
T>B cells
Anti-proliferative agent

54
Q

Inhibits IM PDH, blocks nucleotide synthesis
T>B cells
Anti-proliferative agent

A

Mycophenolate Mofetil

55
Q

Indications: Mycophenolate Mofetil

A

2nd line for transplant, AI disease, vasculitis

56
Q

MOA: Infliximab

A

anti-TNFa

57
Q

MOA: Adalimumab

A

anti-TNFa

58
Q

MOA: Certolizumab

A

anti-TNFa

59
Q

MOA: Golimumab

A

anti-TNFa

60
Q

anti-TNFa (x4)

A

Infliximab, Adalimumab, Certolizumab, Golimumab

61
Q

Indications: Infliximab, Adalimumab, Certolizumab, Golimumab (anti-TNFa)

A

Psoriasis, psoriatic arthritis, IBD, RhA, ank spond

62
Q

MOA: Etanercept

A

Inhibits TNFa and TNFB

63
Q

Inhibits TNFa and TNFB

A

Etanercept

64
Q

Indications: Etanercept

A

Psoriasis, psoriatic arthritis, IBD, RhA, ank spond

65
Q

MOA: Ustekinumab

A

ab inhibits IL-12 and IL-23

66
Q

ab inhibits IL-12 and IL-23

A

Ustekinumab

67
Q

Indications: Ustekinumab

A

Psoriasis, psoriatic arthritis, Crohn’s

68
Q

MOA: Secukinumab

A

ab vs. IL17A

69
Q

ab vs. IL17A

A

Secukinumab

70
Q

Indications: Secukinumab

A

Ank spond, psoriasis, psoriatic arthritis,

71
Q

MOA: Denosumab

A

ab vs. RANK ligand, ↓osteoclasts

72
Q

ab vs. RANK ligand, ↓osteoclasts

A

Denosumab

73
Q

Indications: Denusumab

A

Osteoporosis

74
Q

MOA: Ipilimumab

A

mab vs CTLA4

Boosts immune system by blocking checkpoints, ↑T cell activation

75
Q

mab vs CTLA4

Boosts immune system by blocking checkpoints

A

Ipilimumab

76
Q

Indications: Ipilimumab

A

Advanced melanoma

77
Q

MOA: Pemibrolizumab/Nivolumab

A

ab vs. PD-1

Boosts immune system by blocking checkpoints, ↑T cell activation

78
Q

ab vs. PD-1

Boosts immune system by blocking checkpoints, ↑T cell activation

A

Pemibrolizumab/Nivolumab

79
Q

Indications: Pemibrolizumab/Nivolumab

A

Advanced melanoma

Laura Path Recall (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions